CEP 3800
Latest Information Update: 26 Oct 2011
Price :
$50 *
At a glance
- Originator Cephalon
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 26 Mar 2007 Discontinued - Preclinical for Pain in USA (PO)
- 04 Mar 2003 No development reported - Preclinical for Pain in USA (unspecified route)
- 05 Dec 2000 Preclinical development for Pain in USA (Unknown route)